press releases rule

Archives: Search / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

Dec 22, 2014
-- First-in-Class Drug Candidate to Prevent C. difficile Ahead of Schedule for Phase 2 Testing to Begin in 1st Quarter 2015 --
Dec 2, 2014
-- First-in-Class Clinical Program Targets Protection of Microbiome to Prevent Overgrowth of Deadly C. difficile Infection Linked with Use of IV Antibiotics --
Nov 24, 2014
-- Phase 1a and 1b Trials to Use SYN-004 to Protect Microbiome; Intended to Prevent Overgrowth of Potentially Deadly C. difficile Bacteria --
Nov 14, 2014
-- Company Completes $18.9 Million Net Registered Direct Offering; Finalizes Plans for Start of Clinical Trials in C. difficile and C-IBS --
Nov 6, 2014
-- Conference Call Scheduled for Friday, November 14, 2014, at 8:30 a.m. EST --
 

Print Email RSS